NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $56.84 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$56.86 +0.02 (+0.04%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$55.81▼$57.2850-Day Range$51.52▼$65.5352-Week Range$25.36▼$66.02Volume558,769 shsAverage Volume790,421 shsMarket Capitalization$2.89 billionP/E Ratio189.47Dividend YieldN/APrice Target$62.30Consensus RatingModerate Buy Company Overview AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation. AtriCure also offers products for managing post-operative pain. Founded in 2000, AtriCure is headquartered in Mason, Ohio, and serves customers in the United States and international markets.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreATRC MarketRank™: 2.676373262735 of 5 starsAtriCure scored higher than 54% of companies evaluated by MarketBeat, and ranked 470th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingAtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for AtriCure is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAtriCure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth13.64% Earnings GrowthEarnings for AtriCure are expected to grow by 13.64% in the coming year, from $0.44 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is 189.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.16.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is 189.47, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.45.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.00% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in AtriCure has recently increased by 0.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.72 News SentimentAtriCure has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AtriCure this week, compared to 4 articles on an average week.Search Interest4 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,172,263.00 in company stock.Percentage Held by Insiders4.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesAtriCure (NASDAQ:ATRC) Raised to Strong-Buy at Wall Street ZenNovember 14 at 1:25 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Atricure (ATRC) and CytomX Therapeutics (CTMX)November 13 at 5:01 PM | theglobeandmail.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount. | Base Camp Trading (Ad)AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference TranscriptNovember 9, 2026 | seekingalpha.comAtriCure: A New Quality Metric Could Put A Clip In Nearly Every SternotomyNovember 7, 2026 | seekingalpha.comAtriCure (NASDAQ:ATRC) Stock: Insider Salvatore Privitera Sells 8,404 SharesNovember 7, 2026 | americanbankingnews.comInsider Selling: AtriCure (NASDAQ:ATRC) Insider Sells 8,404 Shares of StockNovember 6, 2026 | insidertrades.comAtriCure (NASDAQ:ATRC) Sets New 12-Month High Following Earnings BeatNovember 6, 2026 | americanbankingnews.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $39.56 at the start of the year. Since then, ATRC stock has increased by 43.7% and is now trading at $56.84. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) announced its earnings results on Tuesday, November, 3rd. The medical device company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.23. The medical device company had revenue of $154.45 million for the quarter, compared to the consensus estimate of $151.05 million. AtriCure had a net margin of 2.52% and a trailing twelve-month return on equity of 4.01%. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? Top institutional investors of AtriCure include State Street Corp (4.18%), GW&K Investment Management LLC (1.78%), First Eagle Investment Management LLC (0.57%) and Public Sector Pension Investment Board (0.51%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Chevron (CVX), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Verizon Communications (VZ), C3.ai (AI), CVS Health (CVS) and Delta Air Lines (DAL). Company Calendar Last Earnings11/03/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ATRC's financial health is in the Green zone, according to TradeSmith. ATRC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,350Year Founded2000Price Target and Rating Average Price Target for AtriCure$62.30 High Price Target$70.00 Low Price Target$44.00 Potential Upside/Downside+9.6%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.30 Trailing P/E Ratio189.47 Forward P/E Ratio113.68 P/E GrowthN/ANet Income-$11.45 million Net Margins2.52% Pretax Margin2.75% Return on Equity4.01% Return on Assets3.03% Debt Debt-to-Equity Ratio0.17 Current Ratio4.33 Quick Ratio3.29 Sales & Book Value Annual Sales$534.53 million Price / Sales5.41 Cash Flow$0.31 per share Price / Cash Flow181.60 Book Value$9.89 per share Price / Book5.75Miscellaneous Outstanding Shares50,920,000Free Float48,885,000Market Cap$2.89 billion OptionableOptionable Beta1.22 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ATRC) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredGlobal Industrial Powerhouse Taps Nasdaq Drone MicrocapA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.